文献速递骨显像与常规 SPECT肿瘤 PET/CT

99mTc-maraciclatide单光子发射计算机断层显像检测骨转移瘤中αvβ3整合素表达:检出与治疗反应评估

Imaging αvβ3 integrin expression in skeletal metastases with 99mTc-maraciclatide single-photon emission computed tomography: detection and therapy response assessment.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-02-02

本研究纳入17例骨为主转移性前列腺癌男性,在阿比特龙治疗前(17例)及治疗12周后(11例)行99mTc-maraciclatide全身平面及SPECT/CT显像,测量肿瘤/正常骨(T:N)与肿瘤/肌肉(T:M)比值及CT胡斯菲尔德单位(HU)。结果显示转移灶特异性摄取该显像剂,硬化性病灶T:M比值低于溶骨性病灶(4.22 vs 7.04,p=0.02);无进展患者SPECT T:M比值下降(-27.2%,p=0.036),进展患者则升高。

要点

  • 99mTc-maraciclatide在骨转移灶中特异性蓄积,符合αvβ3整合素表达增高。
  • 基线硬化性病灶(389-740 HU)T:M比值低于溶骨性病灶(46-381 HU),分别为4.22 vs 7.04(p=0.02)。
  • 治疗12周后,无进展患者SPECT T:M比值下降(-27.2%,p=0.036),进展患者则升高(20.2%)。

核心结论

  • 99mTc-maraciclatide在骨转移灶中蓄积,符合αvβ3整合素表达增高。
  • CT密度较低的转移灶摄取更高,提示摄取与破骨细胞活性相关。
  • 治疗12周后平面及SPECT T:M比值变化在进展与无进展患者间存在差异,99mTc-maraciclatide显像可能成为评估早期反应的方法。

研究设计与样本

  • 研究纳入17例骨为主转移性前列腺癌男性,在开始阿比特龙治疗前(n=17)及治疗12周后(n=11)行99mTc-maraciclatide全身平面及SPECT/CT显像。
  • 每例受试者最多测量5个目标转移灶的肿瘤/正常骨(T:N)比值、肿瘤/肌肉(T:M)比值及CT胡斯菲尔德单位(HU)。
  • 由对研究扫描不知情的肿瘤科医生采用常规标准评估至24周的临床反应。

主要发现

  • 治疗前转移灶显示特异性99mTc-maraciclatide蓄积:平面T:N和T:M比值均值分别为1.43和3.06;SPECT T:N和T:M比值分别为3.1和5.19。
  • 基线硬化性病灶(389-740 HU)T:M比值低于少硬化/溶骨性病灶(46-381 HU),分别为4.22 vs 7.04(p=0.02)。
  • 进展患者(PD;n=5)平面T:N和T:M比值分别升高0.29%和12.1%,SPECT T:N和T:M比值分别升高11.9%和20.2%。
  • 无进展患者平面T:N和T:M比值分别变化0.27%和-8.0%(p分别为1.0和0.044),SPECT T:N和T:M比值分别变化-21.9%和-27.2%(p分别为0.3和0.036)。
  • CT HU百分比变化与SPECT T:M比值百分比变化呈负相关(r=-0.59,p=0.006)。

临床怎么用

  • 原文结论认为99mTc-maraciclatide显像可能成为评估早期治疗反应的方法,未给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting αvβ3 integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. METHODS: The study group comprised 17 men with bone-predominant metastatic PCa who underwent whole-body planar and single-photon emission computed tomography/computed tomography (SPECT/CT) imaging with 99mTc-maraciclatide before (n = 17) and 12 weeks after (n = 11) starting treatment with abiraterone. Tumour to normal bone (T:N) ratios, tumour to muscle (T:M) ratios and CT Hounsfield units (HU) were measured in up to five target metastases in each subject. An oncologist blinded to study scans assessed clinical responses up to 24 weeks using conventional criteria. RESULTS: Before treatment, metastases showed specific 99mTc-maraciclatide accumulation (mean planar T:N and T:M ratios 1.43 and 3.06; SPECT T:N and T:M ratios 3.1 and 5.19, respectively). Baseline sclerotic lesions (389-740 HU) showed lower T:M ratios (4.22 vs. 7.04, p = 0.02) than less sclerotic/lytic lesions (46-381 HU). Patients with progressive disease (PD; n = 5) showed increased planar T:N and T:M ratios (0.29 and 12.1%, respectively) and SPECT T:N and T:M ratios (11.9 and 20.2%, respectively). Patients without progression showed decreased planar T:N and T:M ratios (0.27 and -8.0%, p = 1.0 and 0.044, respectively) and SPECT T:N and T:M ratios (-21.9, and -27.2%, p = 0.3 and 0.036, respectively). The percentage change in CT HU was inversely correlated with the percentage change in SPECT T:M ratios (r = -0.59, p = 0.006). CONCLUSIONS: 99mTc-maraciclatide accumulates in PCa bone metastases in keeping with increased αvβ3 integrin expression. Greater activity in metastases with lower CT density suggests that uptake is related to osteoclast activity. Changes in planar and SPECT T:M ratios after 12 weeks of treatment differed between patients with and without PD and 99mTc-maraciclatide imaging may be a potential method for assessing early response.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cook GJR, Azad GK, Taylor BP, et al. Imaging αvβ3 integrin expression in skeletal metastases with 99mTc-maraciclatide single-photon emission computed tomography: detection and therapy response assessment. Eur J Nucl Med Mol Imaging. 2018. PMID: 29396636. doi:10.1007/s00259-017-3926-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。